Logo image of TRT

TRIO-TECH INTERNATIONAL (TRT) Stock Fundamental Analysis

NYSEARCA:TRT - NYSE Arca - US8967122057 - Common Stock - Currency: USD

5.59  0 (-0.07%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to TRT. TRT was compared to 110 industry peers in the Semiconductors & Semiconductor Equipment industry. TRT has an excellent financial health rating, but there are some minor concerns on its profitability. TRT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TRT has reported negative net income.
In the past year TRT had a positive cash flow from operations.
Of the past 5 years TRT 4 years were profitable.
TRT had a positive operating cash flow in each of the past 5 years.
TRT Yearly Net Income VS EBIT VS OCF VS FCFTRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M

1.2 Ratios

Looking at the Return On Assets, with a value of 0.05%, TRT is in line with its industry, outperforming 49.09% of the companies in the same industry.
TRT has a Return On Equity of 0.06%. This is comparable to the rest of the industry: TRT outperforms 49.09% of its industry peers.
The Return On Invested Capital of TRT (0.04%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for TRT is significantly below the industry average of 10.87%.
The last Return On Invested Capital (0.04%) for TRT is well below the 3 year average (4.20%), which needs to be investigated, but indicates that TRT had better years and this may not be a problem.
Industry RankSector Rank
ROA 0.05%
ROE 0.06%
ROIC 0.04%
ROA(3y)3.88%
ROA(5y)2.51%
ROE(3y)5.73%
ROE(5y)3.71%
ROIC(3y)4.2%
ROIC(5y)N/A
TRT Yearly ROA, ROE, ROICTRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4 6 8

1.3 Margins

TRT has a Profit Margin (0.05%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of TRT has declined.
Looking at the Operating Margin, with a value of 0.05%, TRT is in line with its industry, outperforming 45.45% of the companies in the same industry.
TRT's Operating Margin has improved in the last couple of years.
TRT has a worse Gross Margin (25.88%) than 76.36% of its industry peers.
TRT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 0.05%
PM (TTM) 0.05%
GM 25.88%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y-8.9%
GM growth 3Y2.49%
GM growth 5Y2.07%
TRT Yearly Profit, Operating, Gross MarginsTRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20 25

More info and screens

7

2. Health

2.1 Basic Checks

TRT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for TRT has been increased compared to 1 year ago.
TRT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TRT has been reduced compared to a year ago.
TRT Yearly Shares OutstandingTRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TRT Yearly Total Debt VS Total AssetsTRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

TRT has an Altman-Z score of 3.93. This indicates that TRT is financially healthy and has little risk of bankruptcy at the moment.
TRT has a Altman-Z score of 3.93. This is comparable to the rest of the industry: TRT outperforms 58.18% of its industry peers.
TRT has a debt to FCF ratio of 2.30. This is a good value and a sign of high solvency as TRT would need 2.30 years to pay back of all of its debts.
The Debt to FCF ratio of TRT (2.30) is better than 65.45% of its industry peers.
TRT has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
TRT has a better Debt to Equity ratio (0.01) than 65.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 2.3
Altman-Z 3.93
ROIC/WACC0
WACC11.29%
TRT Yearly LT Debt VS Equity VS FCFTRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

TRT has a Current Ratio of 4.89. This indicates that TRT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TRT (4.89) is better than 71.82% of its industry peers.
A Quick Ratio of 4.54 indicates that TRT has no problem at all paying its short term obligations.
TRT's Quick ratio of 4.54 is fine compared to the rest of the industry. TRT outperforms 78.18% of its industry peers.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
TRT Yearly Current Assets VS Current LiabilitesTRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TRT have decreased strongly by -100.45% in the last year.
TRT shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -9.82% yearly.
Looking at the last year, TRT shows a very negative growth in Revenue. The Revenue has decreased by -14.65% in the last year.
The Revenue has been growing slightly by 1.54% on average over the past years.
EPS 1Y (TTM)-100.45%
EPS 3YN/A
EPS 5Y-9.82%
EPS Q2Q%-804.82%
Revenue 1Y (TTM)-14.65%
Revenue growth 3Y9.24%
Revenue growth 5Y1.54%
Sales Q2Q%-29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRT Yearly Revenue VS EstimatesTRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
TRT Price Earnings VS Forward Price EarningsTRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TRT is valued cheaper than 100.00% of the companies in the same industry.
TRT's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 71.71
EV/EBITDA 0.26
TRT Per share dataTRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRIO-TECH INTERNATIONAL

NYSEARCA:TRT (8/12/2025, 8:20:01 PM)

5.59

0 (-0.07%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)05-19 2025-05-19
Earnings (Next)09-22 2025-09-22
Inst Owners16.54%
Inst Owner Change0.06%
Ins Owners25.82%
Ins Owner Change1.16%
Market Cap24.09M
Analysts0
Price TargetN/A
Short Float %0.28%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF 71.71
P/OCF 22.31
P/B 0.75
P/tB 0.75
EV/EBITDA 0.26
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.39%
OCF(TTM)0.25
OCFY4.48%
SpS8.25
BVpS7.5
TBVpS7.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.05%
ROE 0.06%
ROCE 0.05%
ROIC 0.04%
ROICexc 0.08%
ROICexgc 0.08%
OM 0.05%
PM (TTM) 0.05%
GM 25.88%
FCFM 0.95%
ROA(3y)3.88%
ROA(5y)2.51%
ROE(3y)5.73%
ROE(5y)3.71%
ROIC(3y)4.2%
ROIC(5y)N/A
ROICexc(3y)7.45%
ROICexc(5y)N/A
ROICexgc(3y)7.45%
ROICexgc(5y)N/A
ROCE(3y)5.9%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y11.52%
ROICexc growth 3YN/A
ROICexc growth 5Y11.52%
OM growth 3YN/A
OM growth 5Y6.23%
PM growth 3YN/A
PM growth 5Y-8.9%
GM growth 3Y2.49%
GM growth 5Y2.07%
F-Score6
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 2.3
Debt/EBITDA 0.17
Cap/Depr 26.75%
Cap/Sales 2.09%
Interest Coverage 0.25
Cash Conversion 38.59%
Profit Quality 1768.42%
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z 3.93
F-Score6
WACC11.29%
ROIC/WACC0
Cap/Depr(3y)49.65%
Cap/Depr(5y)43.62%
Cap/Sales(3y)5.01%
Cap/Sales(5y)4.28%
Profit Quality(3y)151.17%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100.45%
EPS 3YN/A
EPS 5Y-9.82%
EPS Q2Q%-804.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.65%
Revenue growth 3Y9.24%
Revenue growth 5Y1.54%
Sales Q2Q%-29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.08%
EBIT growth 3YN/A
EBIT growth 5Y7.87%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-90.51%
FCF growth 3Y56.1%
FCF growth 5Y4.6%
OCF growth 1Y-86.42%
OCF growth 3Y15.97%
OCF growth 5Y-10.48%